Southern Finance and Economics, March 4th - Today, Pfizer announced that it is a highly selective JAK1 inhibitor and an innovative oral small molecule targeted drug called Xibico; Reg; The new indication for age expansion has been officially approved by the National Medical Products Administration (NMPA) of China for the treatment of moderate to severe atopic dermatitis (AD) in adolescents and adults aged 12 and above. (21st Century Business Herald)